Allspring Global Investments Holdings LLC Raises Position in Masimo Co. (NASDAQ:MASI)

Allspring Global Investments Holdings LLC increased its holdings in Masimo Co. (NASDAQ:MASI) by 5,340.9% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,394 shares of the medical equipment provider’s stock after buying an additional 2,350 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Masimo were worth $319,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. NBC Securities Inc. increased its stake in Masimo by 47.1% in the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 73 shares during the last quarter. GAMMA Investing LLC increased its stake in Masimo by 75.0% in the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 111 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in Masimo by 133.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 200 shares during the last quarter. Lazard Asset Management LLC increased its stake in Masimo by 5,730.0% in the first quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock valued at $85,000 after acquiring an additional 573 shares during the last quarter. Finally, HHM Wealth Advisors LLC increased its stake in Masimo by 25.0% in the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after acquiring an additional 125 shares during the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on MASI. BTIG Research increased their target price on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research note on Friday, September 20th. Finally, Piper Sandler reissued an “overweight” rating on shares of Masimo in a research note on Friday, October 18th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $145.33.

Masimo Stock Up 0.1 %

Shares of NASDAQ:MASI opened at $144.22 on Friday. The stock’s 50-day moving average price is $129.44 and its 200-day moving average price is $125.22. Masimo Co. has a 12-month low of $75.36 and a 12-month high of $153.93. The stock has a market capitalization of $7.67 billion, a P/E ratio of 98.11 and a beta of 0.97. The company has a current ratio of 2.09, a quick ratio of 1.15 and a debt-to-equity ratio of 0.55.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.77 by $0.09. Masimo had a net margin of 3.94% and a return on equity of 14.07%. The business had revenue of $496.30 million during the quarter, compared to analyst estimates of $493.92 million. During the same period last year, the business posted $0.62 earnings per share. Masimo’s quarterly revenue was up 9.0% compared to the same quarter last year. On average, equities analysts anticipate that Masimo Co. will post 3.88 earnings per share for the current year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.